Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-08-2018 | Letter to the Editor

The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy

Authors: Dan Călugăru, Mihai Călugăru

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 8/2018

Excerpt

Dear Editor: …

Garweg JG, Zirpel JJ, Gerhardt C, Pfister IB (2018) The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol 256:823–831CrossRef

Călugăru D, Călugăru M (2018) Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 256:233–235CrossRef

Grover SG, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRef

Călugăru D, Călugăru M (2017) Long-term remission of neovascular age-related macular degeneration with as-needed anti-vascular endothelial growth factor therapy. Retina 37:108–110CrossRef

Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol 173:145–146CrossRef

Jaffe GJ, Kaiser PK, Thompson D et al (2016) Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 123:1856–1864CrossRef

Călugăru D, Călugăru M (2017) High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 255:2067–2068CrossRef

Călugăru D, Călugăru M (2018) Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 256:627–629CrossRef

Călugăru D, Călugăru M (2017) Intravitreal dexamethasone implant as adjuvant treatment for bevacizumab- and ranibizumab-resistant neovascular age-related macular degeneration. Retina 37:78–79CrossRef

10.

Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174:185–186CrossRef

Title: The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy
Authors: Dan Călugăru
Mihai Călugăru
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-018-4004-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2018

Vitreoretinal disease diagnosis, management, and clinical pearls by Ingrid U. Scott, Carl D. Regillo, Harry W. Flynn, Jr., Gary C. Brown (2017) pp. 640, Hardback ISBN: 9781626231337 Thieme Publishers

Optical coherence tomography angiography in pachychoroid spectrum diseases

Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy

Fixation behavior in macular dystrophy assessed by microperimetry

Central 10-degree visual field change following non-penetrating deep sclerectomy in severe and end-stage glaucoma: preliminary results

Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab